Heart failure (HF) constitutes a significant disease burden in the USA. Its prevalence has doubled between 1990–2020, showing ...

The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

CAMBRIDGE, England--(BUSINESS WIRE)--As the European distributor of INVOKANA ® (canagliflozin) and VOKANAMET ® (canagliflozin and metformin) Mundipharma welcomes the news that SGLT2i’s, including ...

Examining the risk factors for trastuzumab-related cardiotoxicity in a predominantly Hispanic South Texas population: A descriptive study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced ...

A new Northwestern Medicine study has shed light on how a class of diabetes drugs may protect the kidneys—not just by ...

A retrospective cohort study found that sodium-glucose cotransporter 2 inhibitors were associated with a reduced risk of chronic kidney disease (CKD) in adults with type 2 diabetes. Sodium-glucose ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...